AN INGREDIENT WITH A DISTINCT BIOLOGICAL STORY
From lipid signaling to your next product concept.
Oleoylethanolamide, or OEA, is a naturally occurring fatty acid ethanolamide related to oleic acid. It belongs to a class of bioactive lipids that help translate nutritional signals into biological responses. Its best-known research themes are satiety, feeding behavior and the regulation of lipid metabolism.
For nutraceutical brands, this offers a focused starting point for a metabolic wellness concept: a named molecule, an identifiable pathway and a body of research to evaluate. Olikong introduces OEA as a B2B ingredient for brands, formulation teams, manufacturers and distributors.
01
Satiety-focused concepts
Explore the literature on fullness and eating behavior when developing an adult weight-management product brief.
02
Metabolic wellness
Build a science review around lipid signaling and energy utilization, with a clearly defined target population and finished-product objective.
03
Healthy aging portfolios
Consider metabolic wellness as one part of a wider healthy aging strategy, alongside nutrition, movement and everyday wellbeing.
THE SCIENTIFIC RATIONALE
A closer look at the PPAR-α pathway.
PPAR-α is a nuclear receptor involved in the regulation of lipid metabolism. Foundational research by Fu and colleagues identified OEA as a high-affinity ligand for this receptor and linked receptor activation with satiety-related responses in experimental models. [1]
- 01
A lipid-derived signal
OEA provides a connection between the chemistry of fatty acid ethanolamides and research on nutritional signaling.
- 02
Receptor activation
In preclinical work, OEA activates PPAR-α, a receptor that influences the expression of genes involved in lipid metabolism.
- 03
Responses to investigate
Researchers have examined feeding patterns, lipid utilization and body-weight-related outcomes. These are research endpoints to assess against a specific product concept.
This sequence describes a research rationale. It does not predict the performance of a supplied batch or finished supplement.
RESEARCH AT A GLANCE
Understand the evidence behind the opportunity.
Satiety signaling through PPAR-α
Fu et al. studied OEA in experimental systems including mice with and without PPAR-α. The findings connected OEA’s satiety response with this receptor and helped establish the mechanistic basis for subsequent research.
Nature · View the studyLipid mobilization and utilization
Guzmán et al. investigated lipolysis and fatty acid oxidation using cells, isolated tissues and animal models. The study provides a further mechanistic link between OEA, PPAR-α and fat utilization. It is not a human efficacy trial.
Journal of Biological Chemistry · View the studyAppetite and body-composition endpoints
A randomized, double-blind, placebo-controlled study enrolled 60 adults with obesity and analyzed 56 completers over 60 days. It reported changes in appetite-related and anthropometric measurements. The small, specific study population and the material tested matter when interpreting its relevance.
Appetite · View the studyThese are selected studies of OEA, not trials of Olikong’s commercial grade. They do not establish a finished-product claim or a serving recommendation.
FOR R&D AND PROCUREMENT
Connect the science with a workable specification.
- Ingredient name
- Oleoylethanolamide / oleoyl ethanolamide
- Abbreviation
- OEA
- CAS number
- 111-58-0
- Molecular formula
- C₂₀H₃₉NO₂
- Ingredient category
- Fatty acid ethanolamide / bioactive lipid
- Assay, composition & grade
- Confirm against the current offered specification and COA
- Development formats
- Capsule, tablet or blend concepts, subject to grade and process evaluation
Start with the actual grade
Review identity, OEA assay, the test method and the full composition of the material being offered. Agree on relevant quality limits, including contaminants and microbiological requirements where applicable. Request the current specification and available certificate of analysis so R&D and purchasing can assess the same material.
Design the sample trial around your format
For a capsule, consider the target fill weight and the contribution of other ingredients. For tablets or powder blends, define the handling, mixing and processing questions the sample must answer. Solubility, dispersion, compatibility and stability should be assessed for the actual grade and formulation.
Plan the next development step
If your project requires a tailored ingredient presentation or formulation work, explore our CDMO Service. Share the desired specification, target dosage form, destination market and development stage so the technical scope and deliverables can be agreed.
Information to request with your enquiry.
- Current specification, identity and assay method
- Available COA, composition and quality information
- Storage, packaging and shelf-life information
- Sample quantity, minimum order and indicative lead time
- Literature relevant to the intended use and market
Tell us whether you are assessing a new concept, preparing a manufacturing trial or sourcing for an existing formula. A clear brief helps us address the technical and commercial questions together.
Selected scientific references
- Fu et al. Nature (2003). OEA, feeding and PPAR-α — preclinical research.
- Guzmán et al. Journal of Biological Chemistry (2004). OEA and lipid utilization — preclinical research.
- Payahoo et al. Appetite (2018). OEA and appetite-related outcomes — a small human trial.
- PubChem. Oleoylethanolamide identity and chemical identifiers.

